Altos Labs appoints Joan Mannick as CMO to advance cellular rejuvenation
Endpoints News - 04-Aug-2025Her focus is on reversing disease through cellular rejuvenation
Kyle LaHucik
Staff writer at Fierce Biotech
Staff writer at Fierce Biotech since May 2021. Prior to that, he spent 20 months reporting on the funding, M&A and public launches of tech, software and digital health companies as part of Mergermarket's Chicago bureau.
He completed Bachelor's in Journalism at University of Missouri.
Visit website: http://kylelahucik.com/
See also
FierceBiotech
Web resource providing the latest biotech news, articles, and resources related to biotech company news
Details last updated 10-Jul-2021
Articles written by Kyle LaHucik
UK biotech Juvenescence secures over $150m to develop therapies
Endpoints News - 21-May-2025Juvenescence expands pipeline and UAE presence with new funding to tackle age-related diseases
AbbVie joins the obesity drug race with $2.2b Gubra deal
Endpoints News - 03-Mar-2025The pharma giant bets on amylin therapy to enter the weight-loss market
Jupiter Bioventures: transforming early-stage science into biotech success
Endpoints News - 19-Nov-2024A $70m fund takes bold risks to validate ground-breaking ideas and reshape biotech innovation
Elevian has secured $40 million for anti-aging diseases and heart stroke
FierceBiotech - 17-Sep-2021$40 million for clinical research, lead program-stroke recovery focuses GDF11
Unity's senolytic drug reports positive phase 1 data in eye disease patients
FierceBiotech - 06-Jul-2021Begun phase 2 trial including patients with early stage of disease to test its safety and effectiveness